Skip Ribbon Commands
Skip to main content
Sign In
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

LATEST NEWS

David Perez to Retire as President and CEO of Terumo BCT on March 31, 2019; Antoinette Gawin Named Successor

New Collaboration With StafaCT Will Optimize Patient Pathways for Cellular Treatments

Collaborative Global Effort to Advance Blood Safety Moves Forward Across Ghana

Terumo BCT's Spectra Optia® Apheresis System is the First and Only Device on the European Market Indicated to Treat Guillain-Barré Syndrome and Myasthenia Gravis Using Therapeutic Plasma Exchange

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}